Alpers-Huttenlocher Syndrome Platform
Alpers-Huttenlocher Syndrome (Rare Mitochondrial Disease)
Key Facts
About Stemnovate
Stemnovate operates at the intersection of regenerative medicine and drug discovery, providing innovative platforms for multi-organ modelling and cellular assays. The company leverages stem cell reprogramming, microfluidic devices, and computational modelling to create physiologically relevant human and animal tissue models for pharmaceutical R&D. With a business model centered on services, subscriptions, and product sales, it targets both academic and industry partners to enhance precision medicine and streamline drug development. Its strategic partnerships with leading institutions and a focus on rare disease research position it as a specialized player in the preclinical tools market.
View full company profile